



REVOLUTIONIZING LUNG CANCER DETECTION

Help us integrate an emerging form of early detection into Sunnybrook's lung cancer biomarker testing program

Lung cancer is the leading cause of cancer death, yet survival rates are as high as 90 per cent if detected early. Symptoms often aren't noticeable until later stages, which can complicate a timely diagnosis.

Liquid biopsy is a minimally invasive test that detects fragments of cancer cells (biomarkers) circulating in the bloodstream. This test is not yet widely accessible, especially for those with no history of smoking.

Philanthropic support for clinical trials is the best way to demonstrate the efficacy of liquid biopsy for a wide range of cancer biomarkers and make it more accessible. Sunnybrook researchers recently led a world-first clinical trial that showed liquid biopsy could provide a less invasive way to monitor brain cancer. We also developed and fine-tuned liquid biopsy for prostate cancer. Now is the time to amplify discovery for lung cancer detection.

Small blood test, big potential

Liquid biopsy can reveal fragments that a tumour sheds into the bloodstream. These can then be characterized to determine the presence of cancer, and whether it may respond to targeted therapies. What's more: liquid biopsy could potentially replace tissue biopsy when tumour tissue is scarce or too difficult to analyze.

How your support will change outcomes

Liquid biopsy promises more information, less worry and earlier results for patients and their families. Earlier results mean earlier treatment.

Fundraisers like *Crush it with Bev!* play a powerful role in bringing the latest technologies, testing and treatments to patients at Sunnybrook to invent the future of lung cancer care.

As a close friend and loved one of Bev Moir, you know she feels a deep sense of responsibility to raise awareness and support for lung cancer care and research. With your continued support, Sunnybrook will launch clinical research to help validate liquid biopsy in the detection of lung cancer biomarkers with the goal of ensuring more patients receive precise and personalized care when it matters most.

Your support in 2021 enabled the purchase of an Ion Chef. This specialized tool automates lung cancer biomarker testing to ensure accuracy and efficiency, allowing Sunnybrook scientists to test tumour samples faster and increase capacity, so more patients can receive personalized, precision diagnoses and treatments. Thank you.